Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
One important change is that they state, GLP-1 RA therapy may be continued preoperatively in patients without elevated risk of delayed gastric emptying. The risk factors they state include: escalation phase of dosing, higher dose, weekly dosing (as opposed to daily dosing), gastrointestinal symptoms (nausea, vomiting, abdominal pain, dyspepsia, constipation), and medical conditions that may cause delayed gastric emptying
1,2 However, little is known about whether the use of weight loss medications, such as phentermine or GLP-1 medications, is correlated with certain pregnancy and neonatal outcomes
3,6 From Table 1, the number needed to treat (NNT) for the first-line agents range from 1.3 for lacosamide to 8.7 for mirogabalin
Despite statistically significant body weight reduction in phase I, the compounds selectivity and potency profile may have limited the magnitude of weight loss
